Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.100
+0.020 (1.85%)
At close: Mar 20, 2026, 4:00 PM EDT
1.130
+0.030 (2.73%)
After-hours: Mar 20, 2026, 7:29 PM EDT

Fate Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-136.32-186.26-160.93-281.72-212.15
Depreciation & Amortization
12.918.9618.2813.765.85
Stock-Based Compensation
24.9241.543.4678.7354.36
Other Adjustments
-3.845.78-10.72-17.895.53
Change in Receivables
2.62-1.1136.65-29.8-3.16
Changes in Accounts Payable
-9.03-1.66-28.9414.255.91
Changes in Unearned Revenue
-0.01-0.89-41.54-6.38-18.56
Changes in Other Operating Activities
2.660.8211.47-19.16-0.65
Operating Cash Flow
-106.08-122.87-132.26-248.21-162.87
Capital Expenditures
-5.95-0.73-6.15-35.57-50.7
Sale of Property, Plant & Equipment
0.36----
Purchases of Investments
-195.14-317.75-358.81-404.8-968.16
Proceeds from Sale of Investments
311.9330.7477.63607.11694.84
Investing Cash Flow
111.1712.22112.67166.75-324.02
Issuance of Common Stock
-94.820.099.21453.13
Net Common Stock Issued (Repurchased)
-94.820.099.21453.13
Other Financing Activities
5.495.07---
Financing Cash Flow
5.4999.890.099.21453.13
Net Cash Flow
10.57-10.76-19.51-72.25-33.76
Free Cash Flow
-112.04-123.6-138.42-283.77-213.57
FCF Margin
-1685.78%-906.79%-217.86%-294.68%-382.43%
Free Cash Flow Per Share
-0.94-1.09--2.93-2.25
Levered Free Cash Flow
-135.74-169.77-207.81-314.82-270.31
Unlevered Free Cash Flow
-147.13-193.78-237.4-341.48-275.15
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q